Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Luteinizing hormone (LH) is a hormone of the gonadotropin type found normally in the body. It is a glycopolypeptide which is synthesized and secreted by gonadotropic cells from the anterior part of the pituitary gland together with the follicle-stimulating hormone (FSH).
Lutropin alfa is an LH of recombinant origin.
Lutropin alfa is used, accompanied by follitropin (FSH), in infertility treatments to induce ovulation in women with LH deficiency in assisted reproduction programmes.
Afterwards, the human chorionic gonadotropin hormone (hCG) is usually administered to trigger ovulation.
Subcutaneous administration of a daily dose with ovarian ultrasound monitoring or urinary estrogen, up to 35 days according to evolution.
Since the last update we have not found any published data on its excretion in breast milk.
Its high molecular weight makes its excretion in breastmilk very unlikely.
Due to its glyco-proteic nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.
Although it causes an increase in the secretion of estradiol by the follicles (AEMPS 2005), there is no proof that its estrogenic effects decrease milk production.
-------------------------------------------------- --------
BREASTFEEDING and INFERTILITY TREATMENTS
In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:
1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.
2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.
To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).
See below the information of these related products: